Drug maker GSK invests in gene profiling services

By The Associated Press | Posted - Jul. 25, 2018 at 5:18 a.m.

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

LONDON (AP) — Drug maker GlaxoSmithKline says second-quarter revenue was 7.3 billion pounds ($9.6 billion), up 4 percent when discounting currency shifts, amid a promising performance of a new shingles treatment.

Sales of the shingles treatment Shingrix made 167 million pounds, and the company increased its forecast for 2018 sales of the drug to as much as 650 million pounds. GlaxoSmithKline Wednesday reported second-quarter net income of 441 million pounds after a loss of 180 million pounds in the same period last year.

The company also announced a restructuring program aiming to improve competitiveness and cut costs by 400 million pounds annually by 2021. GlaxoSmithKline also agreed to invest $300 million in personal genetic testing service 23andMe as part of deal to use the company's database to develop precision targeted drugs.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

The Associated Press


    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast